<乌鸦传媒>New Drugs Yield Limited Benefit; Big Jump in Drug Prices; AI Boost for Mammo Results News, features, and commentary about cancer-related issues Mar 01, 2024
<乌鸦传媒>PROs for Cutaneous Chronic GVHD After Transplant Tied to Disease Severity, Mortality Baseline QOL, symptom burden could inform risk stratification, treatment decisions Feb 28, 2024
<乌鸦传媒>Amy Schumer's Diagnosis; FDA Yanks Cancer Drug; Nursing Student Murdered Health news and commentary from around the Web gathered by 乌鸦传媒 staff Feb 26, 2024
<乌鸦传媒>Transforming Shots Into Pills; 'Tip of the Iceberg' for TILs? Food Additives Warning News, features, and commentary about cancer-related issues Feb 23, 2024
<乌鸦传媒>Male Fertility Problems in the Family Linked to Cancer Risk Low sperm levels were tied to specific cancers in family members Feb 22, 2024
<乌鸦传媒>Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma No PFS benefit from adding the monoclonal antibody to standard therapy Feb 20, 2024
<乌鸦传媒>For Kids With Sickle Cell Disease Prescribed Opioids, No Patterns of Misuse Emerged Number of vaso-occlusive crises tied to days' supply Feb 19, 2024
<乌鸦传媒>Rush to Publish? Medicare Drug Plan Lawsuit Quashed; Activity Curbs Cancer Pain News, features, and commentary about cancer-related issues Feb 16, 2024
<乌鸦传媒>Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML But it's unlikely stem cell transplants will ever be large-scale cure for HIV, says expert Feb 14, 2024
<乌鸦传媒>FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia Complete response rate of 86%, median event-free survival approaching 4 years with crenolanib Feb 13, 2024
<乌鸦传媒>No Relief From Drug Shortages; New Lymphedema Guideline; A 'Good' Patient No More News, features, and commentary about cancer-related issues Feb 09, 2024
<乌鸦传媒>Pulled Myeloma Drug May Have a Role in Treating the Disease After All Belantamab mafodotin boosts PFS by nearly 2 years when combined with bortezomib, dexamethasone Feb 07, 2024
<乌鸦传媒>All-Oral Therapy Promising in Higher-Risk MDS, CMML In small trial, overall response rate was 95% Feb 05, 2024
<乌鸦传媒>Camp Lejeune Water Contamination Tied to a Range of Cancers, CDC Study Says Health risks now more firmly established, but study falls short of being definitive Feb 01, 2024
<乌鸦传媒>Most Immunocompromised Patients Clear Omicron Infections B-cell malignancies, B-cell treatments associated with longer duration of infection Jan 30, 2024
<乌鸦传媒>When a Revolutionary Cancer Treatment Causes Cancer The potential benefits of CAR T-cell therapies still far outweigh the risks Jan 27, 2024
<乌鸦传媒>CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning Post-treatment cases grow to 22 since products' initial approvals Jan 24, 2024
<乌鸦传媒>FDA Calls for New Boxed Warning on All CAR-T Products Most serious warning would alert patients, providers on potential risk for secondary malignancies Jan 23, 2024
<乌鸦传媒>Gene Therapy for Sickle Cell Disease Likely Cost-Effective if Under $2 Million Lifetime reduction in acute pain episodes should offset high upfront costs of the therapy Jan 22, 2024
<乌鸦传媒>Two Million Cancers; Casgevy OK'd for Thalassemia; Rectal Exams and Prostate Cancer News, features, and commentary about cancer-related issues Jan 19, 2024
<乌鸦传媒>Kate Middleton Hospitalized; Sen. Paul Urges Prison for Fauci; COVID Back in Class Health news and commentary from around the Web gathered by 乌鸦传媒 staff Jan 17, 2024
<乌鸦传媒>Carvedilol No Help in Preventing Heart Failure in Childhood Cancer Survivors While safe, the results do not support use of the drug in anthracycline-exposed survivors Jan 10, 2024
<乌鸦传媒>Direct Thrombin Inhibitor Shows Benefit for Progressing Stroke Urgent anticoagulation with argatroban shows no bleeding downside in EASE trial Jan 09, 2024
<乌鸦传媒>Gene Therapy for Hemophilia Becomes a Reality Uptake of new options for hemophilia A and B has been a bit slow Dec 29, 2023
<乌鸦传媒>Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL Approach could allow for a response-adapted reduction of CHOP Dec 27, 2023 video
<乌鸦传媒>Longer Letermovir Prophylaxis Reduced Risk of Cytomegalovirus Infection After HSCT Randomized study showed extending prophylaxis from 100 to 200 days was effective and safe Dec 27, 2023
<乌鸦传媒>Tisa-Cel Yields Durable Responses in R/R Follicular Lymphoma Our panel of experts discuss 3-year findings from the phase II ELARA study Dec 26, 2023 video
<乌鸦传媒>Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC News, features, and commentary about cancer-related issues Dec 21, 2023
<乌鸦传媒>JAK1 Inhibitor Shows 'Remarkable' Activity in T-Cell Lymphoma Phase II findings on golidocitinib will form the basis of an accelerated approval application Dec 15, 2023
<乌鸦传媒>Hematocrit Stabilized in Polycythemia Vera Treated With Novel Hepcidin Mimetic Rusfertide maintained hematocrit Dec 15, 2023
<乌鸦传媒>Ibrutinib-Venetoclax Improves PFS in R/R Mantle Cell Lymphoma Will results revive ibrutinib role in MCL following withdrawal of accelerated approval? Dec 13, 2023
<乌鸦传媒>'Half-Matched' BMTs Effective in Severe Sickle Cell Disease High survival rates observed in patients not normally suitable for transplant Dec 13, 2023
<乌鸦传媒>Pomalidomide Cuts Severe Epistaxis in Genetic Bleeding Disorder 24 weeks of daily treatment significantly reduced recurrent nosebleeds in HHT trial Dec 13, 2023
<乌鸦传媒>Four Drugs Top Three for Upfront Treatment of Multiple Myeloma Adding anti-CD38 antibodies boosts response and PFS, but timing, sequencing, cost questioned Dec 13, 2023
<乌鸦传媒>Menin Inhibitor Yields 63% ORR in Heavily Pretreated Acute Leukemia Investigational drug revumenib now under review at FDA for KMT2A-rearranged disease Dec 12, 2023
<乌鸦传媒>Ruxolitinib Combinations Reduce Spleen Volume in Myelofibrosis Combos with navitoclax or pelabresib led to more patients achieving reductions Dec 12, 2023
<乌鸦传媒>Axatilimab Shows Efficacy in Recurrent/Refractory GVHD Highest overall response rate and least toxicity seen with lowest dose Dec 11, 2023
<乌鸦传媒>MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia No advantage for MRD-negative patients in first remission after induction, regardless of FLT3 ITD Dec 11, 2023
<乌鸦传媒>A Closer Look at the Approval of CRISPR/Cas9 Gene Therapy for Sickle Cell Disease This landmark event brings up broader considerations and implications for other diseases Dec 11, 2023
<乌鸦传媒>ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission Better 2-year PFS, OS, but not applicable to primary refractory disease Dec 10, 2023
